J&J Restructuring Organizes Pharma Division Into Three Businesses
This article was originally published in The Pink Sheet Daily
Executive Summary
Three therapeutic-based business units will bring together commercial, R&D and operational organizations, effective June 1.
You may also be interested in...
Johnson & Johnson’s Scodari Announces Retirement As Firm Reorganizes
Christine Poon will assume direct responsibility for the firm’s pharmaceutical and biologics business.
Johnson & Johnson’s Scodari Announces Retirement As Firm Reorganizes
Christine Poon will assume direct responsibility for the firm’s pharmaceutical and biologics business.
J&J Plans Dapoxetine Meeting With FDA, Awaits Agency Actions
Firm’s pharma sales stall as it awaits FDA action on pending NDAs and Concerta citizen petition.